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Abstract
Introduction: Limited data describe outcomes on second-line antiretroviral therapy (ART) among children globally. Our objec-
tive was to contribute data on outcomes among children living with HIV after initiation of second-line ART in the context of
routine care within a large global cohort collaboration.
Methods: Patient-level data from 1993 through 2015 from 11 paediatric HIV cohorts were pooled. Characteristics at switch
and through two years of follow-up were summarized for children who switched to second-line ART after starting a standard
first-line regimen in North America, Latin America, Europe, Asia, Southern Africa (South Africa & Botswana) and the rest of
sub-Saharan Africa (SSA). Cumulative incidences of mortality and loss to follow-up (LTFU) were estimated using a competing
risks framework.
Results: Of the 85,389 children on first-line ART, 3,555 (4%) switched to second-line after a median of 2.8 years on ART
(IQR: 1.6, 4.7); 69% were from Southern Africa or SSA and 86% of second-line regimens were protease inhibitor-based. At
switch, median age was 8.4 years and 50% had a prior AIDS diagnosis. Median follow-up after switch to second-line ranged
from 1.8 years in SSA to 5.3 years in North America. Median CD4 counts at switch to second-line ranged from 235 cells/
mm3 in SSA to 828 cells/mm3 in North America. Improvements in CD4 counts were observed over two years of follow-up,
particularly in regions with lower CD4 counts at second-line switch. Improvements in weight-for-age z-scores were not
observed during follow-up. Cumulative incidence of LTFU at two years was <5% in all regions except SSA (7.1%) and Southern
Africa (7.4%). Risk of mortality was <3% at two years of follow-up in all regions, except Latin America (4.9%) and SSA (5.5%).
Conclusions: Children switched to second-line ART experience CD4 count increases as well as low to moderate rates of LTFU
and mortality within two years after switch. Severe immune deficiency at time of switch in some settings suggests need for
improved recognition and management of treatment failure in children.
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1 | INTRODUCTION
In 2018, there were an estimated 1.7 million children living
with HIV globally and 160,000 new paediatric infections [1].
With the recommendation for immediate antiretroviral ther-
apy (ART) [2], substantial gains in survival have been observed
among children living with HIV [3]. The success of ART, how-
ever, brings new challenges, including the need to optimize
regimens throughout the lifespan as children age into adoles-
cence and adulthood. Evaluating critical ART outcomes such
as HIV disease progression, mortality and loss to follow-up
(LTFU) is needed to inform treatment management strategies
to increase long-term effectiveness, as well as to help forecast
future antiretroviral drug needs.
Responses to first-line ART among children have been eval-
uated in large randomized trials and observational studies [4-
12]. Studies evaluating outcomes on second-line ART in chil-
dren; however, have been limited by small sample sizes in
both resource-rich and resource-limited settings [6,13-21]. Of
the four published studies on second-line ART with larger
sample sizes, ranging from 111 to 277 children, three were
conducted in Thailand or the Asia-Pacific region [18-20], and
one followed Ugandan children who were switched to a lopi-
navir/ritonavir (LPV/r)-based second-line regimen [21]. These
studies observed improvements in CD4 counts after switch to
a second-line regimen, with an increase of 267 cells/mm3 in
mean CD4 counts after 48 weeks of follow-up in the Ugandan
study [21], and 463 cells/mm3 in median CD4 counts after
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3.3 years of follow-up in the largest study conducted in Asia
[20]. No deaths were observed over 48 weeks of follow-up
among the Ugandan children on second-line ART, and less
than 2% of children died in the studies of Asian children on
second-line ART [18-21].
The studies described above were conducted while experi-
ence with second-line ART among children was still limited in
many settings. The Collaborative Initiative for Paediatric HIV
Education & Research (CIPHER) global cohort collaboration
provides a unique opportunity to further evaluate outcomes
associated with second-line ART in the context of routine
care, as it reflects the world’s largest combined cohort of chil-
dren living with HIV on ART.
2 | METHODS
2.1 | Study population
The CIPHER cohort collaboration brings together existing
paediatric HIV observational cohorts to address key knowl-
edge gaps in the care and treatment of children and adoles-
cents living with HIV globally. Eleven international networks
contributed data from 1993 through 2015 from a total of
47 countries: Baylor International Pediatric AIDS Initiative
(BIPAI), European Pregnancy and Paediatric HIV Cohort Col-
laboration (EPPICC), the International epidemiology Data-
bases to Evaluate AIDS (IeDEA) Consortium (Regions: Asia-
Pacific, Caribbean, Central and South America network (CCA-
SAnet), Central Africa, East Africa, West Africa and Southern
Africa), International Maternal Pediatric Adolescent AIDS
Clinical Trials (IMPAACT) Protocols P219C and P1074, Opti-
mal Models (ICAP at Columbia University), and the Pediatric
HIV/AIDS Cohort Study (PHACS). All participating networks
received local ethics approvals to transfer anonymized indi-
vidual participant-level data for this collaboration to the
University of Cape Town (Cape Town, South Africa) for data
management using a standardized protocol. The pooling of
data at the University of Cape Town was approved by the
University of Cape Town Health Research Ethics Committee
(UCT HREC (reference 264/2014)). The dataset was then
sent to University College London (London, United Kingdom)
for analysis.
Eligible children were less than 10 years of age at cohort
enrolment as a proxy for perinatal HIV infection, were less
than 18 years of age at initiation of a “standard” first-line
combination ART regimen, and were seen in clinic for at least
one visit after initiating ART. Children documented as horizon-
tally infected with HIV (e.g. by blood products, unsafe injec-
tions, sexual transmission) and those enrolled in clinical trials
of treatment monitoring, switch or interruption strategies
were excluded.
2.2 | Study definitions
“Standard” combination ART was defined as a regimen with at
least three drugs, including at least two nucleoside/nucleotide
reverse transcriptase inhibitors (NRTIs) plus either a non-nu-
cleoside reverse transcriptase inhibitor (NNRTI) or a ritonavir-
boosted protease inhibitor (PI). Switch to second-line was
defined as: (i) change of at least one NRTI plus either change
in drug class (NNRTI to PI, or vice versa) or PI change; (ii)
change from single to dual PI; or (iii) addition of a new drug
class. Second-line regimens including more than two drug
classes were hierarchically classified based on whether they
followed an NNRTI- or PI-based first-line ART. If first-line was
an NNRTI-based ART regimen, the hierarchy was integrase
strand transfer inhibitor (INSTI)>LPV/r>Other PI>efavirenz
(EFV)>Other NNRTI. If first-line was a PI-based ART regimen,
this was INSTI>EFV>nevirapine (NVP)>LPV/r>Other PI>Other
NNRTI.
Geographical region was categorized as: North America,
Latin America (Caribbean, Central and South America), Eur-
ope, Asia, Southern Africa (South Africa and Botswana) and
the rest of sub-Saharan Africa (SSA). Southern Africa was
considered separately from SSA because this region had
earlier introduction of LPV/r-based regimens as first-line
and earlier rollout of viral load (VL) monitoring. Immuno-
logic classification of HIV disease was based on World
Health Organization (WHO) guidelines, and AIDS was
defined as a WHO Stage 3/4 or a Centers for Disease
Control and Prevention (CDC) Stage C clinical diagnosis
[22-24]. Treatment monitoring strategy was derived from
the frequency and availability of CD4 and VL measures
across all children receiving ART within a cohort, as
described previously [12].
2.3 | Study outcomes
Outcomes of interest included CD4 counts and weight-for-
age z-scores (WAZ) at one and two years of follow-up after
switch to second-line ART. Follow-up was limited to two years
based on the average duration of available follow-up in SSA
after switch to second-line ART. Changes in CD4 counts and
WAZ from switch to second-line ART were also summarized.
The British 1990 growth reference centiles were used to
transform weight measures to WAZ for all regions due to the
availability of standards across all age ranges [25]. Additional
outcomes of interest included mortality and LTFU at one and
two years of follow-up. Children were considered as LTFU if
they had no visit for more than one year (or more than two
years for the North American and European cohorts due to
annual reporting) before the last observed visit in their cohort.
Children who met the definition of LTFU were censored at
their last clinic visit.
2.4 | Statistical analyses
This analysis was an intent-to-treat analysis, meaning that chil-
dren were not excluded from analyses due to subsequent dis-
continuation or change of regimen after initial switch to
second-line ART when summarizing outcomes. Demographic
and clinical characteristics at start of second-line ART as well
as follow-up duration were summarized by region. Clinical and
laboratory outcomes, including CD4 counts and WAZ, at one
and two years after start of second-line ART were then com-
pared descriptively by region. CD4 counts and WAZ were
additionally compared descriptively over follow-up by CD4
count at switch, age at switch, WAZ at switch and second-line
regimen type. Summary statistics included only those with
available data. The proportion of children with missing mea-
sures, however, was noted. Cumulative incidences of mortality
and LTFU at one and two years of follow-up were estimated
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using a competing risks framework [26] with LTFU treated as
a competing risk for mortality, and vice versa. Transfer out
was considered a competing risk for both outcomes. Stata ver-
sion 14.2 (College Station, TX) was used to conduct all analy-
ses.
3 | RESULTS
3.1 | Study population characteristics at start of
second-line ART
Of over 170,000 children included in the CIPHER global
cohort collaboration from the 11 participating networks,
85,389 (50%) initiated a “standard” first-line ART regimen
between 1993 and 2015 and were followed for switch to sec-
ond-line. Of these, 3,555 (4%) initiated a second-line regimen,
and outcomes were assessed over two years of follow-up
from the time of switch (Figure S1). Children from Southern
Africa and SSA accounted for almost 70% of the overall study
population, with an additional 13% from Europe, 12% from
Asia, 3% from Latin America and 2% from North America (Fig-
ure 1). Table 1 shows demographic and clinical characteristics
of the study population at start of second-line ART. Forty-four
percent of the study population was female and 73% of chil-
dren initiated second-line ART between 2007 and 2012. Chil-
dren who switched to second-line ART spent a median of
2.8 years (interquartile range (IQR): 1.6, 4.7) on first-line ART
before switching; time on first-line ART ranged from a median
of 2.0 years in North America to 3.7 years in SSA. Median
age at start of second-line ART was 8.4 years (IQR: 5.3, 11.4),
though there was regional variability with children in North
America starting second-line at earlier ages (median (IQR): 4.1
(1.9, 7.5) years).
While 69% of clinics met our definition for having routine
CD4 and VL testing, this varied greatly across and within
regions, with 13% of sites in SSA defined as having routine VL
testing and 33% having targeted VL testing. At start of sec-
ond-line ART, 41% of children had severe immune deficiency
and 50% ever had an AIDS-defining diagnosis. Of note, severe
immune deficiency at switch to second-line ART was close to
60% in the rest of SSA as compared to 26% in Southern
Africa, where 100% of clinic sites had routine CD4 and VL
monitoring. This disparity in HIV progression on ART was also
evidenced by the proportion of children who progressed to an
AIDS diagnosis after start of first-line ART and prior to switch
to second-line ART in SSA compared to Southern Africa (20%
vs. 0.6% respectively). Of the children with available CD4
counts at switch to second-line ART (78%), over a quarter had
CD4 counts <200 cells/mm3, though this varied greatly across
regions, from 3.6% of children in North America to 36% in
Asia, 44% in SSA and 48% in Latin America. Of the 62% of
children with VL measurements at start of second-line, 82%
had VLs > 1000 copies/mL. Median WAZs were below refer-
ence norms in all regions, with children in Asia and SSA fre-
quently severely underweight at the start of second-line ART
(median (IQR): Asia, 1.9 (3.0, 0.9); SSA, 2.0 (3.0,
1.1)).
3.2 | Second-line ART regimens
Among the 86% of participants who were on an NNRTI-based
first-line regimen, the majority (89%) initiated an LPV/r-based
second-line regimen, particularly in Southern Africa (99%) and
SSA (94%) (Figure 2a). In the other regions, second-line regi-
mens with alternate PIs (e.g. atazanavir, darunavir) or INSTIs
(e.g. raltegravir) were more prevalent, particularly in North
America where 67% and 4% of children started a second-line
regimen with an alternate PI or INSTI respectively. Among the
14% of children who were on a PI-based first-line regimen,
the majority (65%) initiated a second-line ART with EFV,
though second-line regimens with NVP were more prevalent
in SSA (75%) (Figure 2b).
Figure 1. Global distribution of study population on second-line ART (N = 3555).
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3.3 | Follow-up and outcomes after switch to
second-line ART
Observed years of follow-up after switch to second-line ART
ranged by region, from a median (IQR) of 1.8 (0.7, 3.3) in SSA,
2.2 (1.0, 4.0) in Southern Africa, 3.4 (1.9, 5.3) in Asia, 3.7 (2.1,
5.9) in Latin America, 4.0 (2.1, 6.8) in Europe, to 5.3 (2.7, 8.4)
in North America. Children in almost all regions experienced
improvements in median CD4 counts from switch to second-
line ART at one and two years of follow-up, with more
Table 1. Demographic and clinical characteristics of children at the start of second-line ART within the CIPHER cohort collaboration
(N = 3555)
North
America
Latin
America Europe Asia
Southern
Africa Rest of SSA Total
Total N 72 123 464 442 1255 1199 3555
Median age in years (IQR) 4.1 (1.9,
7.5)
10.3 (6.7,
13.8)
8.2 (4.2,
12.0)
7.1 (5.2,
9.5)
8.3 (5.3,
11.2)
9.3 (6.0,
11.9)
8.4 (5.3, 11.4)
Female sex, N (%) 39 (54.2) 62 (50.4) 241 (51.9) 169 (38.2) 553 (44.1) 500 (41.7) 1564 (44.0)
Calendar year, N (%)
Up to 2000 24 (33.3) 0 (0.0) 12 (2.6) 0 (0.0) 0 (0.0) 0 (0.0) 36 (1.0)
2001 to 2003 14 (19.4) 9 (7.3) 42 (9.1) 0 (0.0) 7 (0.6) 0 (0.0) 72 (2.0)
2004 to 2006 14 (19.4) 19 (15.5) 113 (24.4) 67 (15.2) 119 (9.5) 38 (3.2) 370 (10.4)
2007 to 2009 8 (11.1) 42 (34.2) 130 (28.0) 145 (32.8) 360 (28.7) 246 (20.5) 931 (26.2)
2010 to 2012 9 (12.5) 49 (39.8) 137 (29.5) 203 (45.9) 583 (46.5) 688 (57.4) 1669 (47.0)
2013 to 2015 3 (4.2) 4 (3.3) 30 (6.5) 27 (6.1) 186 (14.8) 227 (18.9) 477 (13.4)
Median years on
first-line ART (IQR)
2.0 (1.0, 3.5) 3.5 (2.2, 6.0) 2.9 (1.2, 5.5) 2.7 (1.7, 4.1) 2.8 (1.6, 4.6) 3.7 (1.8, ;4.7) 2.8 (1.6, 4.7)
Monitoring strategy, N (%)a
Clinical only 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 126 (10.5) 126 (3.5)
Routine CD4 0 (0.0) 55 (44.7) 0 (0.0) 0 (0.0) 0 (0.0) 520 (43.4) 575 (16.2)
Routine CD4 + targeted VL 0 (0.0) 0 (0.0) 3 (0.7) 0 (0.0) 0 (0.0) 399 (33.3) 402 (11.3)
Routine CD4 + routine VL 72 (100.0) 68 (55.3) 461 (99.4) 442 (100.0) 1255 (100.0) 154 (12.8) 2452 (69.0)
AIDS diagnosis, N (%)
None 63 (87.5) 114 (92.7) 354 (76.3) 218 (49.3) 463 (36.9) 560 (46.7) 1772 (49.9)
Prior to start of first-line 7 (9.7) 7 (5.7) 86 (18.5) 164 (37.1) 784 (62.5) 402 (33.5) 1450 (40.8)
Between first- and
second-line
2 (2.8) 2 (1.6) 24 (5.2) 60 (13.6) 8 (0.6) 237 (19.8) 333 (9.4)
WHO immune status, N (%)b
None 25 (44.6) 31 (29.3) 183 (46.5) 96 (24.4) 496 (50.4) 160 (19.1) 991 (35.8)
Mild 18 (32.1) 9 (8.5) 55 (14.0) 42 (10.7) 137 (13.9) 72 (8.6) 333 (12.0)
Advanced 6 (10.7) 8 (7.6) 50 (12.7) 37 (9.4) 95 (9.7) 112 (13.4) 308 (11.1)
Severe 7 (12.5) 58 (54.7) 106 (26.9) 219 (55.6) 256 (26.0) 492 (58.9) 1138 (41.1)
CD4 countc
N (%) with
available measures
55 (76.4) 107 (87.0) 400 (86.2) 395 (89.4) 987 (78.7) 842 (70.2) 2786 (78.4)
Median (IQR) 828 (454,
1399)
239 (63,
661)
595 (330,
1046)
315 (127,
675)
577 (353,
884)
235 (81,
561)
445 (185, 818)
<200 cells/mm3, N (%) 2 (3.6) 51 (47.7) 46 (11.5) 141 (35.7) 117 (11.9) 374 (44.4) 731 (26.2)
>500 cells/mm3, N (%) 38 (69.1) 35 (32.7) 233 (58.3) 144 (36.5) 581 (58.9) 230 (27.3) 1261 (45.3)
CD4%c
N (%) with available measures 56 (77.8) 72 (58.5) 382 (82.3) 370 (83.7) 936 (74.6) 615 (51.3) 2431 (68.4)
Median (IQR) 30 (21, 35) 20 (9, 30) 23 (15, 33) 14 (7, 22) 22 (15, 29) 13 (6, 21) 19 (11, 28)
HIV viral loadc
N (%) with
available measures
53 (73.6) 56 (45.5) 414 (89.2) 323 (73.1) 1034 (82.4) 305 (25.4) 2185 (61.5)
≥1000 copies/mL, N (%) 44 (83.0) 47 (83.9) 290 (70.1) 298 (92.3) 808 (78.1) 296 (97.1) 1783 (81.6)
<1000 copies/mL, N (%) 9 (17.0) 9 (16.1) 124 (30.0) 25 (7.7) 226 (21.9) 9 (3.0) 402 (18.4)
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dramatic improvements in the regions with lower CD4 counts
at start of second-line (e.g. Latin America, Asia, SSA) (Fig-
ure 3). In North America, median CD4 count at the start of
second-line ART was in the upper range of normal and stayed
stable during two years of follow-up after switch to second-
line. Overall improvements in median CD4 counts from switch
to second-line ART were 180 cells/mm3 (IQR: 11, 422) and
199 cells/mm3 (IQR: 41, 496) at one and two years of fol-
low-up respectively. Median CD4 counts were >500 cells/
mm3 across all regions at one and two years after switch to
second-line ART (Tables S1 and S2). Of note, CD4 measure-
ments were available for over 75% of children in all regions
across all time points including at switch to second-line ART,
except for SSA where CD4 count availability ranged from
69% to 70% across all time points. In additional subgroup
analyses, there were increases in median CD4 counts over
two years after switch across CD4 count categories at switch,
age categories at switch, WAZ categories at switch, and sec-
ond-line regimen type, with more substantial increases among
subgroups with lower CD4 counts at switch to second-line
ART (Figure S2).
In contrast to CD4 counts, little change in WAZ was
observed in any region after switch to second-line ART (Fig-
ure S3). There were also no substantial improvements in WAZ
over two years after switch by CD4 count at switch, age at
switch and second-line regimen type, though there were some
small improvements over time among children with CD4
counts <500 cells/mm3, children who were <10 years of age,
and children who initiated PI- or NNRTI-based second-line
ART. More substantial improvements in WAZ were observed
over time among children who were severely wasted at switch
(i.e. WAZ <3), though median WAZ was still less than three
standard deviations below the mean two years after switch
(Figure S4).
The cumulative incidence of LTFU at two years was <5% in
all regions except Southern Africa and SSA, where it was 7.1%
(95% confidence interval (CI): 5.7%, 8.8%) and 7.4% (95% CI:
5.8%, 9.2%) respectively (Figure 4). The cumulative risk of
mortality was less than 3% at two years in North America,
Europe, Asia and Southern Africa (Figure 5). In the first six
months after second-line ART, the risk of mortality was 4.9%
(95% CI: 2.0, 9.8) in Latin America, with no additional deaths
over follow-up, and 5.5% (95% CI: 4.2, 7.1) in SSA at two
years. Among the 92 children who were reported to have died
within two years of switch to second-line ART, their median
age at switch was 8.2 years (IQR: 5.2, 12.8). 85/92 (92.4%)
had initiated a PI-based second-line regimen, 5/92 (5.4%) an
NNRTI-based regimen and 2/92 (2.2%) an INSTI-based regi-
men. The median CD4 count, CD4% and WAZ at switch to
second-line among the subgroup who died within two years
after switch and with available measures were 90 cells/mm3
(IQR: 23, 377; n:74), 5% (IQR: 2, 16; n: 59) and 3.8 (IQR:
5, 1.9; n:85) respectively.
4 | DISCUSSION
We describe the largest cohort of children living with HIV on
second-line ART to date, and specifically include the largest
population of children on second-line ART from Africa, where
HIV disease burden is highest. Almost 70% of children in the
analysis were from Southern Africa and the rest of SSA.
Our study reports on the cumulative incidences of LTFU
and mortality among children on second-line ART. We
observed low to moderate risks of LTFU and mortality across
all regions, though higher risks were observed among children
in Southern Africa and SSA, which is consistent with prior
studies evaluating ART outcomes in these regions [27]. It is
important to note that this cohort reflects children living with
HIV who have survived for long enough to access both first-
and second-line ART. Moreover in many resource-limited set-
tings, switching to second-line is less likely to occur if provi-
ders are unable to identify children as failing treatment or are
uncomfortable switching them to second-line regimens which
are often more difficult to adhere to. Thus, this cohort reflects
a group of paediatric survivors who have had consistent and
reliable engagement with clinical care over the course of their
treatment and who have thus had better potential for medica-
tion adherence or access to clinical management supports
such as adherence counselling before the time of ART switch.
Table 1. (Continued)
North
America
Latin
America Europe Asia
Southern
Africa Rest of SSA Total
WAZc
N (%) 51 (70.8) 119 (96.8) 342 (73.7) 366 (82.8) 934 (74.4) 1141 (95.2) 2953 (83.1)
Median (IQR) 0.4 (1.2,
0.5)
1.5 (2.7,
0.6)
0.1 (0.9,
0.7)
1.9 (3.0,
0.9)
1.2 (2.1,
0.4)
2.0 (3.0,
1.1)
1.5 (2.5, 0.5)
ART, antiretroviral treatment; IQR, interquartile range; SSA, sub-Saharan Africa; VL, HIV viral load; WAZ, weight-for-age z-score; WHO, World
Health Organization.
aThis is a cohort-level variable, derived from the frequency and availability of CD4 and VL measures across all ART-treated children as previously
described. [12]; bnone: CD4%> 35% for those <12 months of age,> 30% for those 12 to 35 months of age, >25% for those 36 to 59 months of
age, and a CD4 count of >500 cells/mm3 for those five years or older; Mild: CD4% of 30–35% for those < 12 months of age, 25% to 30% for
those 12 to 35 months of age, 20–25% for those 36 to 59 months of age, and a CD4 count of 350 to 499 cells/mm3 for those five years or
older; Advanced: CD4% of 25–29% for those < 12 months of age, 20–24% for those 12 to 35 months of age, 15% to 19% for those aged 36 to
59 months, and a CD4 count of 200 to 349 cells/mm3 for those five years or older; Severe: CD4% < 25% for those <12 months of age, <20%
for those 12 to 35 months of age, <15% for those 35 to 59 months of age, and a CD4 count <200 cells/mm3 for those five years or older [21];
csummary statistics calculated among those with available data.
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At two years of follow-up, we observed improvements in
CD4 counts similar to what have been reported in previous
studies conducted primarily in Asia [14,16,18-21]. While it is
reassuring to observe immune recovery after switch to sec-
ond-line ART, we noted a large proportion of children with
severe immune deficiency and AIDS progression at the time
of switch to second-line ART in some settings. This suggests
that recognition of treatment failure and transition to second-
line regimens is often very late. While it is true that second-
line ART became available in later calendar years in settings
such as SSA, our findings suggest a need for improved recog-
nition and management of treatment failure in children.
In contrast to CD4 count, we did not observe improve-
ments in WAZ over two years of follow-up after switch to
second-line ART. This suggests that second-line ART is not
necessarily associated with shorter-term improvements in
WAZ among children with perinatal HIV infection. One other
study also reported no improvements in WAZ after 96 weeks
on second-line ART [19]. Many children therefore remained
severely underweight in some settings, which has implications
for future cognitive development and mortality [28,29]. More
data are needed to understand why we did not observe gains
in weight after switch to second-line ART.
While the incidence of switch to second-line among children
globally is overall very low after initiation of ART [12], the cur-
rent generation of children who switched to second-line ART
did so after a median of less than three years on first-line
ART and at a median of 8.4 years of age. Previous studies of
children on PI-based second-line ART have reported a low
prevalence of major resistance mutations to second-line
agents [15,21], suggesting that these regimens should be effi-
cacious in the long-term with appropriate adherence support.
However, third-line and fourth-line options will become a
necessity with lifelong therapy. Ensuring access to new, better
Figure 2. Second-line ART regimens by region and first-line ART regimen.
(a) After an NNRTI-based first-line ART regimen. (b) After a PI-based first-line ART regimen. ART, antiretroviral therapy; EFV, efavirenz; INSTI,
integrase strand transfer inhibitor; LPV/r, lopinavir/ritonavir; NNRTI, non-nucleoside reverse transcriptase inhibitor; NVP, nevirapine; PI, protease
inhibitor; SSA, sub-Saharan Africa.
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tolerated antiretroviral drugs and supporting medication
adherence will be continuing and important needs.
While our study represents a large global analysis, we could
not effectively elucidate switches to second-line ART due to
treatment failure because we could not evaluate risks of viro-
logic failure across regions due to varying VL monitoring
strategies and testing access. Particularly in regions where tar-
geted VL monitoring is prevalent, it would be difficult to inter-
pret risks of virologic failure as children with clinical signs of
disease progression would be more likely to receive a VL test.
For our primary outcomes of interest, CD4 count and WAZ,
the proportion of missing data ranged from 6% to 31% and
3% to 29% respectively, across regions and time points. Our
data, however, is reflective of routine clinical care and the
contexts in which treatment decisions are being made for chil-
dren living with HIV globally. Given the heterogeneity in avail-
able data, we also did not report on height measures or
calculate body mass index, limiting our ability to fully under-
stand growth responses after switch to second-line. The
expansive calendar time span of the study, while reflective of
the regional disparity in when children began enrolling in HIV
care services, also added to the heterogeneity of our data
Figure 3. Median CD4 counts with interquartile ranges over two years of follow-up by region.
Figure 4. Cumulative incidence of loss to follow-up by region.
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with respect to available and recommended second-line ART
options and disease monitoring strategies across calendar time
and region. We were also unable to evaluate longer-term out-
comes after switch to second-line ART across all regions as
second-line ART became available in later calendar years in
SSA, thus shortening the available follow-up time. Lack of
access to new ART drugs and limited follow-up in some
regions also restricted our ability to define switch to third-line
ART and thus durability of second-line. Our observations on
the outcomes after switch to second-line ART, however, can
inform need for third-line ART in specific regions.
5 | CONCLUSIONS
Children living with perinatal HIV who switched to second-line
ART in our global cohorts have responded well, with increases
in CD4 counts and low to moderate rates of LTFU and mor-
tality within two years after switch. The large proportion of
children with severe immune deficiency at time of switch in
some settings emphasizes the need for improved recognition
and management of treatment failure in children. The early
age at switch among children and adolescents on second-line
ART, also emphasizes the importance of providing access to
more durable regimens to preserve their long-term treatment
options and health through adulthood.
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